Basser Executive Director Susan Domchek, MD, received a Fellow of the American Society of Clinical Oncology distinction at the American Society of Clinical Oncology annual meeting. The honor recognizes ASCO members’ extraordinary volunteer service, dedication, and commitment to the society.
Findings to be presented during a plenary session at the American Society of Clinical Oncology meeting show that a PARP inhibitor significantly reduced the risk that breast cancer would return when given to patients with the BRCA mutation. Basser Executive Director Susan Domchek, MD, serves as lead investigator of the Penn trial.
Susan Domchek, MD, Basser Executive Director, was featured in a story about Latinas and BRCA mutations. Despite the high prevalence of the mutations, awareness of hereditary cancer risks and genetic testing is low among this group, limiting their options for early treatment, she said.
Penn Medicine News
Many pancreatic cancer patients with BRCA and PALB2 mutations saw their tumors stop growing or shrink substantially after being switched from chemotherapy to the PARP inhibitor rucaparib, according to results from a clinical trial led by Basser Center researchers.
Susan Domchek, MD, Basser Center Executive Director, was quoted in a Wall Street Journal article that profiled a woman’s experience with genetic testing and a surprising family tree that led her to make decisions about her cancer care.
Philly Voice highlights our Black & BRCA initiative, which launched last fall to help raise awareness about genetic testing in the Black community.
Susan Domchek, MD, Executive Director of the Basser Center, was quoted in a story about the growing understanding of genetic risk factors for breast cancer and the ongoing debate on recommendations for genetic testing.
Med Page Today
In an op-ed, Basser Director of Genetics Katherine L. Nathanson, MD, joined other Penn physicians in offering strategies to “nudge” oncologists to overcome race as a heuristic in decision-making.
Basser researcher Kim Reiss Binder, MD, was featured in a series of videos on the latest in pancreatic cancer research and therapies, discussing immunotherapies, early detection, and metastatic disease.
Basser Executive Director Susan Domchek, MD, was quoted in a story on the ambiguity of certain genetic tests and how “variants of unknown significance” (VUS) can guide cancer treatments, despite a lack of evidence to support those decisions.
Penn Medicine News
Several genetic mutations previously linked to breast cancer and included on commercial genetic tests were found not to increase a woman’s risk of disease, according to a population study published today in the New England Journal of Medicine, involving the Basser Center and Penn Medicine.
Nature Cell Biology
Researchers led by Basser Director of Basic Science Roger Greenberg, MD, PhD, found that eliminating an enzyme called ALC1 can potentially increasing the effectiveness of PARP inhibitors in cancer treatment.
This helpful list of cancer survivors to follow on Instagram includes Alejandra Campoverdi, our partner on LATINX & BRCA.
Everviolet talked to Basser Young Leadership Council co-chair Erika Stallings about her experience with BRCA and hereditary cancer.
Penn Medicine scientists including Basser Executive Director Susan Domchek, MD, and Basser Director of Genetics Katherine Nathanson, MD, recently published a paper on the PennChart Genomics Initiative.
Penn Medicine News
We’re honored to award the 2020 Basser Global Prize to Bella Kaufman, MD, of Sheba Medical Center at Tel Hashomer in Israel. Dr. Kaufman has had a crucial role in the development of PARP inhibitors for the treatment of BRCA-related cancers.
Early and repeated exposures to diagnostic imaging, such as X-rays and CT scans, may increase the risk of testicular cancer, according to a new study published in PLOS ONE and led by Katherine L. Nathanson, MD, Basser Director of Genetics.